文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

孕产妇百日咳疫苗接种预防婴儿感染和疾病的有效性:新南威尔士州公共卫生网络病例对照研究

Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study.
PubMed 文献 · Vaccine · 2018-03-01

该研究采用1:1匹配病例对照设计,于2015年8月16日至2016年8月17日在澳大利亚新南威尔士州开展,评估孕产妇接种3组分无细胞百日咳疫苗对6月龄以下婴儿的保护效果。共纳入117例病例和117例对照,总体疫苗有效性(VE)对6月龄以下婴儿为39%(95%CI -12至66%),对3月龄以下婴儿为69%(95%CI 13-89%),对住院的VE为94%(95%CI 59-99%)。作者认为孕产妇疫苗接种对预防婴儿严重疾病高度有效,但预防非住院疾病效果较低,总体VE低于既往研究。

要点

  • 6月龄以下婴儿总体VE为39%(95%CI -12至66%),未达统计学显著。
  • 3月龄以下婴儿VE为69%(95%CI 13-89%),对住院的VE为94%(95%CI 59-99%)。
  • 孕产妇疫苗接种对预防婴儿严重百日咳高度有效,但对感染或轻症保护效果较低。

核心结论

  • 孕产妇接种3组分无细胞百日咳疫苗对预防婴儿严重疾病高度有效,但预防非住院疾病效果较低。
  • 本研究总体VE低于既往研究,提示孕产妇疫苗接种在预防感染或轻症方面效果较低。

研究设计与样本

  • 1:1匹配病例对照研究,于2015年8月16日至2016年8月17日开展。
  • 病例为实验室或医生报告、实验室确诊(核酸检测或培养)且发病时年龄<6月龄的婴儿。
  • 每个对照婴儿从同一地理区域公立医院出生者中随机选取,出生日期在病例出生日期前后3天内。
  • 采用条件logistic回归计算比值比(OR),疫苗有效性(VE)计算为1-OR。
  • 共纳入117例病例和117例对照。

主要发现

  • 6月龄以下婴儿总体VE为39%(95%CI -12至66%),未达统计学显著。
  • 3月龄以下婴儿VE为69%(95%CI 13-89%)。
  • 对住院的VE为94%(95%CI 59-99%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infants are at the highest risk of severe complications - including death - as a result of pertussis infection. Controlling pertussis in this group has been challenging, particularly in those too young to be vaccinated. Following revised national recommendations in March 2015, the state of New South Wales, Australia, introduced a funded maternal vaccination campaign at 28 - 32 weeks of gestation using a 3-component tetanus-diphtheria-acellular pertussis vaccine (dTpa; Boostrix, GSK). This study aimed to assess the effectiveness of maternal vaccination and add to the growing body of evidence for this strategy. METHODS: A 1:1 matched case-control study was conducted between 16 August 2015 and 17 August 2016. Cases were laboratory or doctor notified, laboratory confirmed (nucleic acid testing or culture) and aged <6 months at onset. Each control infant was randomly selected from public hospital births in the same geographical area in the period up to 3 days before and after the case's birthdate. Odds ratios (OR) were calculated using conditional logistic regression. Vaccine effectiveness (VE) was calculated as 1 - OR. FINDINGS: In total, 117 cases and 117 controls were recruited. The overall VE estimate was non-significantly protective for infants <6 months old (VE 39%, 95% CI -12 to 66%). Higher VE was observed for infants <3 months old (VE 69%, 95% CI 13-89%) and against hospitalisation (VE 94%, 95% CI 59-99%). INTERPRETATION: Maternal pertussis vaccination with a 3-component acellular vaccine was found to be highly effective at preventing severe disease in infants, but was less effective at preventing disease which did not require hospitalisation. The overall VE reported in this study was lower than in prior studies and suggests that maternal vaccination, while an effective strategy at preventing severe pertussis, is less effective at protecting against infection or mild disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saul N, Wang K, Bag S, et al. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. Vaccine. 2018. PMID: 29501321. doi:10.1016/j.vaccine.2018.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。